

Gibson Dunn Advises Korsana Biosciences on Merger with Cycleron Therapeutics

Firm News | April 7, 2026

Gibson Dunn is advising Korsana Biosciences on its merger with Cycleron Therapeutics, Inc. and concurrent \$380 million financing.

The firm's corporate team includes partners Ryan Murr and Branden Berns and associate Evan Shepherd.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Evan Shepherd](#)

Related Capabilities

[Life Sciences](#)

[Mergers and Acquisitions](#)